Department of hematology, Antioquia Oncology Center, Envigado, Colombia.
Case Study
World Journal of Advanced Research and Reviews, 2023, 20(01), 1261-1267
Article DOI: 10.30574/wjarr.2023.20.1.2208
Received on 18 September 2023; revised on 26 October 2023; accepted on 28 October 2023
Mycosis fungoides is the most common primary cutaneous T-cell lymphoma. It is a non-Hodgkin lymphoma that begins in the skin and is characterized by a slow clinical evolution of three stages: macules, plaques and tumors. The advanced stage includes lymph node, visceral, or blood involvement, and requires skin-directed therapy associated with systemic medications. The case of a 49-year-old female patient with a diagnosis of mycosis fungoides in the malar region since July 2019 is presented, initially treated between November 2019 and March 2020 with 3 cycles of the CHOP chemotherapy regimen - cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin) and prednisone without achieving any clinical response. Subsequently without follow-up or treatment. In February 2023, progression of the disease was documented due to worsening of the lesion in the malar region and involvement of the glutes and back, additionally with cervical lymphadenopathy but without bone marrow involvement. She is considered a candidate for liposomal doxorubicin, with which she has completed 5 cycles to date with excellent clinical response. Current reassessment studies using positron emission tomography show complete tumor response. A bone marrow transplant is the therapeutic option that is being considered at the moment.
Case report; Mycosis fungoides; Progression; Chemotherapy; Liposomal doxorubicin; Transplant
Preview Article PDF
Juan Sebastián Lopera Valencia and Diana Margarita Otero de la Hoz. Mycosis Fungoides: Case report of progression successfully treated with liposomal doxorubicin. World Journal of Advanced Research and Reviews, 2023, 20(1), 1261-1267. Article DOI: https://doi.org/10.30574/wjarr.2023.20.1.2208